ID   CAL-72
AC   CVCL_1113
SY   CAL 72; CAL72; Cal72; Centre Antoine Lacassagne-72
DR   BTO; BTO:0002089
DR   CLO; CLO_0002188
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 842
DR   BioSample; SAMN03473545
DR   cancercelllines; CVCL_1113
DR   Cell_Model_Passport; SIDM00930
DR   ChEMBL-Cells; CHEMBL3308718
DR   ChEMBL-Targets; CHEMBL1075414
DR   Cosmic; 906827
DR   Cosmic; 1074399
DR   Cosmic-CLP; 906827
DR   DepMap; ACH-001715
DR   DSMZ; ACC-439
DR   DSMZCellDive; ACC-439
DR   EGA; EGAS00001000978
DR   GDSC; 906827
DR   GEO; GSM320825
DR   GEO; GSM1669655
DR   IARC_TP53; 21214
DR   LINCS_LDP; LCL-1419
DR   PharmacoDB; CAL72_175_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1113
DR   Wikidata; Q54808412
RX   PubMed=10389764;
RX   PubMed=11668190;
RX   PubMed=12631258;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: African.
CC   Doubling time: 66 hours (Note=At 17th passage) (PubMed=10389764); ~40-50 hours (DSMZ=ACC-439).
CC   Karyotypic information: Has lost chromosome Y (PubMed=10389764).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=67.94%; Native American=0.09%; East Asian, North=1.27%; East Asian, South=0%; South Asian=24.79%; European, North=0%; European, South=5.91% (PubMed=30894373).
CC   Derived from site: In situ; Bone, patella; UBERON=UBERON_0002446.
ST   Source(s): Cosmic-CLP=906827; DepMap=ACH-001715; DSMZ=ACC-439
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8
ST   D16S539: 10
ST   D18S51: 19
ST   D19S433: 13
ST   D21S11: 28
ST   D2S1338: 21
ST   D3S1358: 18
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 11,14
ST   FGA: 19,22
ST   Penta D: 8
ST   Penta E: 15,19
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 38
//
RX   PubMed=10389764; DOI=10.1002/(SICI)1097-0215(19990719)82:2<282::AID-IJC20>3.0.CO;2-R;
RA   Rochet N., Dubousset J., Mazeau C., Zanghellini E., Farges M.-F.,
RA   Stora de Novion H., Chompret A., Delpech B., Cattan N., Frenay M.,
RA   Gioanni J.;
RT   "Establishment, characterisation and partial cytokine expression
RT   profile of a new human osteosarcoma cell line (CAL 72).";
RL   Int. J. Cancer 82:282-285(1999).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=12631258; DOI=10.1034/j.1600-0609.2003.02766.x;
RA   Rochet N., Leroy P., Far D.F., Ollier L., Loubat A., Rossi B.;
RT   "CAL72: a human osteosarcoma cell line with unique effects on
RT   hematopoietic cells.";
RL   Eur. J. Haematol. 70:43-52(2003).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//